{
    "title": "Apellis' drug better than Soliris in improving hemoglobin levels in trial",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-7861473/Apellis-drug-better-Soliris-improving-hemoglobin-levels-trial.html",
    "date": "2020-01-07",
    "keywords": [
        "pnh",
        "drug",
        "hemoglobin",
        "blood",
        "market",
        "pegcetacoplan",
        "soliris",
        "apellis",
        "manojna",
        "maddipatla",
        "trisha",
        "roy",
        "improvement",
        "alexion",
        "analyst",
        "approval",
        "apl2",
        "life",
        "jan",
        "tuesday",
        "disorder",
        "leader",
        "hemoglobinuria",
        "half",
        "latestage",
        "trial",
        "dominance",
        "quarter",
        "popandfade",
        "phenomenon",
        "failure",
        "effectiveness",
        "acid",
        "dehydrogenase",
        "ldh",
        "madhu",
        "kumar",
        "indicator",
        "hemolysis",
        "breakage",
        "level",
        "reduction",
        "noninferiority",
        "concern",
        "benefit",
        "product",
        "company",
        "study",
        "case",
        "superiority",
        "standard",
        "care",
        "treatment",
        "year",
        "need",
        "breath",
        "chief",
        "officer",
        "cedric",
        "francois",
        "quality",
        "penetration",
        "patient",
        "phil",
        "pathway",
        "complement",
        "system",
        "atrophy",
        "kidney",
        "course",
        "reporting",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}